Laboratory support services related to circulating inflammation markers and prospective risk of noncardia gastric cancer

Ended Purchase Order Awarded Last action

Contract number
HHSN261201600028A
Awardee
Awarding agency
Obligated
$62,224

Award facts

Opportunity
Contract value 100% obligated
$62,224.00 Current and potential, with all options
Completion date 100% complete
  • Current, with exercised options
  • Potential, with all options
NAICS code
621511 Medical Laboratories
Set-aside
No set-aside
Competition
Not Competed under SAP · 1 offer Simplified Acquisition
Pricing
Firm Fixed Price
Place of performance
Boston, MA 02134, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Funding Only Action P00001 · DE-obligation of funds from FY2016 expiring lines. -$7,976
Original award $70,200

About this award

The National Cancer Institute awarded a purchase order to Olink Bioscience AB for $62,224 on September 20, 2016, for laboratory support services related to circulating inflammation markers and prospective risk of noncardiac gastric cancer. Work is performed in Boston, Massachusetts. The order carried a firm fixed price and was subject to de-obligation of funds from expiring FY2016 lines, with ultimate completion on July 12, 2021.

Quick answers

Who was awarded contract HHSN261201600028A?

HHSN261201600028A was awarded to Olink Bioscience AB by National Cancer Institute (National Institutes of Health) on September 20, 2016.

How much is contract HHSN261201600028A worth?

The government has obligated $62,224 on HHSN261201600028A.

Was contract HHSN261201600028A competed?

The extent of competition for HHSN261201600028A was not competed under sap. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award